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BACKGROUND: High-frequency neuromuscular electrical stimulation increases exercise tolerance in patients with
advanced chronic obstructive pulmonary disease (COPD patients). However, it is conceivable that its benefits are
more prominent in patients with better-preserved peripheral muscle function and structure.
OBJECTIVE: To investigate the effects of high-frequency neuromuscular electrical stimulation in COPD patients with
better-preserved peripheral muscle function. Design: Prospective and cross-over study.
METHODS: Thirty COPD patients were randomly assigned to either home-based, high-frequency neuromuscular
electrical stimulation or sham stimulation for six weeks. The training intensity was adjusted according to each
subject’s tolerance. Fat-free mass, isometric strength, six-minute walking distance and time to exercise intolerance
(Tlim) were assessed.
RESULTS: Thirteen (46.4%) patients responded to high-frequency neuromuscular electrical stimulation; that is, they
had a post/pre DTlim .10% after stimulation (unimproved after sham stimulation). Responders had a higher
baseline fat-free mass and six-minute walking distance than their seventeen (53.6%) non-responding counterparts.
Responders trained at higher stimulation intensities; their mean amplitude of stimulation during training was
significantly related to their fat-free mass (r = 0.65; p,0.01). Logistic regression revealed that fat-free mass was the
single independent predictor of Tlim improvement (odds ratio [95% CI] = 1.15 [1.04-1.26]; p,0.05).
CONCLUSIONS: We conclude that high-frequency neuromuscular electrical stimulation improved the exercise
capacity of COPD patients with better-preserved fat-free mass because they tolerated higher training stimulus
levels. These data suggest that early training with high-frequency neuromuscular electrical stimulation before tissue
wasting begins might enhance exercise tolerance in patients with less advanced COPD.
KEYWORDS: Chronic obstructive pulmonary disease; electrical stimulation; body composition; exertion; pulmonary
rehabilitation.
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INTRODUCTION
There is growing evidence that chronic obstructive
pulmonary disease (COPD) has systemic consequences,
including a syndrome of skeletal muscle dysfunction.1 In
this context, several authors have found substantial altera-
tions in muscle structure,2 bioenergetics,3 nutritional status,
4 BODE index5 and function,6 especially but not exclusively
in the appendicular muscles of the lower limbs.7
Exercise training has long been advocated as a useful
rehabilitative strategy for this patient population.8 More
recently, high-frequency neuromuscular electrical stimula-
tion (hf-NMES) has been successfully used as a localized
training modality in severely disabled patients who are
unable to follow formal pulmonary rehabilitation and/or
tolerate higher training intensities.9-12 In these studies, hf-
NMES was applied to patients with the most severe muscle
dysfunction and disease course. However, previous data
from other populations suggest that the effectiveness of hf-
NMES is modulated by the anatomical and functional
integrity of the muscle apparatus; that is, subjects with
better-preserved muscle mass and strength were more
responsive to NMES.13-16 Moreover, the force evoked by
electrical stimulation largely depends on the subject’s
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tolerance to the applied current,14 which might be higher in
less-disabled patients who are more accustomed to the
subjective stress associated with exertion. These issues
suggest that the potential for improvement with hf-NMES
was fully realized in previous studies with end-stage COPD
patients.9-12
Therefore, we performed a prospective trial to determine
whether the potential for exercise capacity improvement
with hf-NMES in COPD patients might be associated with
phenotype characteristics indicative of better-preserved
muscle structure and function. We reasoned that a
confirmation of this hypothesis would have practical
relevance, implying that hf-NMES could be an appropriate
early rehabilitative strategy to use before severe muscle
atrophy and weakness develops in patients with COPD.
METHODS
Subjects
The study group consisted of thirty patients who were
consecutively evaluated at the Federal University of Sa˜o
Paulo’s outpatient COPD clinic. All patients had been
diagnosed with COPD according to the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) criteria;17
that is, they presented with a forced expiratory volume in
one second (FEV1) of ,70% of the predicted value and a
FEV1/forced vital capacity (FVC) of ,0.70. They also
presented with chronic breathlessness (Medical Research
Council dyspnea scale I-III).18 No participant had been
previously enrolled in a pulmonary rehabilitation program.
All participants were at a stable phase of the disease, which
was indicated by no change in medical therapy (including
oral steroid use) or exacerbation of symptoms within the
preceding four weeks. Exclusion criteria were long-term use
of supplemental oxygen; associated locomotor or neurolo-
gical conditions; malignancy; cardiac failure; distal arterio-
pathy; a1-antiprotease deficiency; recent surgery; a severe
endocrine, hepatic or renal disorder; use of anticoagulant
medication and regular physical activity. Before entering the
study, all patients had their pulmonary function optimized
with long-acting bronchodilators and inhaled steroids when
appropriate.
The Research Ethics Committee of the Federal University
of Sa˜o Paulo, Sa˜o Paulo, Brazil (UNIFESP-EPM), approved
the study (Protocol No. 1455/03). All the procedures and
any associated risks were described in detail to the
participants, and written informed consent was obtained.
Data from an ad-interim analysis of a subgroup of patients
(N = 17) who had undergone muscle biopsies were
previously published.19
Design and procedures
This study was a prospective, randomized, crossover, and
sham-controlled study. Patients were assigned to a six-
week, home-based hf-NMES program followed by sham
stimulation or vice-versa. A two-week wash-out period was
included between conditions. After randomization, the
patients were not told which sequence they would follow.
Each evaluation consisted of a three-day protocol: Day 1,
pulmonary function and six-minute walking tests; Day 2,
body composition assessment and incremental and sub-
maximal cardiopulmonary exercise tests; and Day 3,
isokinetic knee strength assessment. The evaluation team
was blinded to the patients’ treatment sequences.
Training protocol
The hf-NMES training protocol was based on a schema
previously proposed by Neder et al.,9 who used a portable,
dual-channel NME stimulator (DualpexH 961 Sport, Quark
Produtos Me´dicos, Brazil). The following training protocol
was chosen to minimize the effects of fatigue on muscle
contractility: (i) symmetrical, biphasic, square-pulsed cur-
rent at 50 Hz; (ii) duty cycle: 2 s on and 10 s off (16%) in the
first week, 5 s on and 25 s (18%) off in the second week, 10 s
on and 30 s off (25%) in the third and fourth weeks, 10s on
and 20 s off (33%) thereafter; and (iii) pulses 300- to 400-ms
wide, using the highest tolerable amplitude (15-20 mA at the
start of the training session, increasing up to 60 mA). This
training protocol was applied to each leg of the sequence
(15 minutes at a time the first week, 30 minutes at a time the
second week and 60 minutes at a time thereafter) five times
per week for six weeks. The sham stimulation protocol
consisted of (i) a symmetrical, biphasic, square-pulsed
current at 50 Hz; (ii) a duty cycle: 2 s on and 10 s off
(16%); (iii) pulses fixed at 200 ms; and (iv) a constant current
intensity of 10 mA. We certified that these settings were not
too high to elicit effective muscle contraction in all patients.
The sham stimulation was applied to each leg for 15 minutes
at a time, three times per week for 6 weeks.
To familiarize the patients with the equipment and detect
possible side effects, active and sham hf-NMES protocols
were initially applied under the guidance of a qualified and
experienced physiotherapist in an outpatient hospital
setting during the first week. During the home-based
training phase, each participant kept a daily user diary that
included his/her impressions during the training sessions.
In addition, the patients came to the laboratory once a week
to adjust the stimulator settings, provide feedback about the
previous week and receive instructions to further adjust the
settings at home.
Table 1 - Baseline characteristics (N = 30).
Variables Mean ¡ SD
Demographic and anthropometric
Age (years ) 63.7 ¡ 7.3
Gender (m/f) 26/4
BMI (kg/m2) 23.8 ¡ 4.2
FFM (kg) 46.9 ¡ 7.1
Lung function
FEV1 (L) 1.42 ¡ 0.48
FEV1 (% predicted) 49.7 ¡ 13.4
FEV1/FVC 48.2 ¡ 8.5
TLC (% predicted) 114.2 ¡ 16.3
RV (% predicted) 189.9 ¡ 52.5
RV/TLC 53.8 ¡ 10.0
DLCO (% predicted) 56.9 ¡ 19.0
Exercise capacity
VO2 peak (% predicted) 70.4 ¡ 16.1
Endurance time (s) 488.4 ¡ 190.5
6MWD (m) 495.6 ¡ 72.9
Peripheral muscle function
Isometric strength (Nm) 132.4 ¡ 36.5
Definition of abbreviations: BMI – body mass index; FFM – fat-free mass;
FEV1 - forced expiratory volume in 1 second; RV - residual volume; TLC -
total lung capacity; DLCO – lung diffusing capacity for carbon monoxide;
VO2 - oxygen uptake; 6MWD – six-minute walking distance
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Measurements
Body composition. Height was obtained while the
subjects stood barefoot and was determined to the nearest
0.5 cm. Body mass was measured with the subjects wearing
light clothing and was established to the nearest 0.1 kg.
Total body bone- and fat-free mass (FFM, kg) was measured
using dual-energy x-ray absorptiometry (DEXA) (Hologic
QDR-4500ATM). The subjects laid on a specially designed
table for 10 to 20 min wearing only a standard hospital
gown. The DEXA scanner performed a series of transverse
scans from head to toe at 1-cm intervals, using the pencil-
beam mode. Data were collected in 120-pixel elements per
transverse scan, with each pixel measuring approximately 5
6 10 mm. FFM depletion was defined as an FFM index
(FFMI = fat-free mass/height2) #15 kg/m2 for females or
#16 kg/m2 for males.20
Pulmonary function tests. Spirometric tests were
performed using the CPF SystemTM (Medical Graphics
Corporation-MGC, St. Paul, MN, USA) with airflow
measured by a calibrated pneumotachograph. The subjects
completed at least three acceptable maximum forced
expiratory maneuvers before and after taking 400 mg of
inhaled salbutamol. A computer-based automated system
(PF-DX SystemTM; Medical Graphics) was used to measure
static lung volumes (total lung capacity [TLC] and residual
volume [RV]) by body plethysmography. Carbon monoxide
diffusing capacity (DLCO) was measured using the modified
Krogh technique (single breath). The subjects performed
two acceptable and reproducible tests, with results within
10% or 3 ml/min/mmHg.
Six-minute walking test. The six-minute walking dis-
tance (6MWD) was measured according to a standardized
protocol.21 Subjects were instructed to walk at their own
pace along a 34.5-m corridor from one end to the other,
covering as much ground as possible in the allotted time.
The technicians encouraged subjects with the standardized
statements ‘‘You’re doing well’’ or ‘‘Keep up the good
work.’’ Subjects were allowed to stop and rest during the
test, but they were instructed to resume walking as soon as
they felt able to do so. Dyspnea (Borg scale), pulse oximetry
(oxyhemoglobin saturation, SpO2, %), and heart rate (HR,
bpm) were assessed at the beginning and end of the test.
The subjects were also asked at the end of the walk whether
they experienced any of the following symptoms: dyspnea,
chest pain, lightheadedness, or leg pain.
Cardiopulmonary exercise testing (CPET). The exercise
tests were carried out on an electromagnetically braked
cycle ergometer (CPE 2000, Medical Graphics Corporation-
MGC, St. Paul, MN, USA) with gas exchange and ventilatory
variables analyzed breath-by-breath using a calibrated,
computer-based exercise system (MGC-CPX System,
Medical Graphics Corp.). Cardiac electrical activity
(CardiO2 System, Medical Graphics Corp.) and SpO2
(Ohmeda Biox 3740, USA) were continuously recorded.
The incremental exercise test consisted of (a) 2 min at rest;
(b) 2 min of real zero-external intensity exercise obtained
with the use of an electrical system that moved the
ergometer flywheel at 50 rpm; (c) an incremental phase;
and (d) a 3-min recovery period. Power (W) was continu-
ously increased in a linear ramp pattern (5 to 20 WNmin-1)
such that the incremental exercise test duration was
greater than 8 min and lower than 12 min for all patients.
The average pulmonary oxygen uptake (V˙ O2, L/min) for
the last 15 s of the ramp was considered representative of
the subject’s peak V˙O2
22. After 40 minutes, the patients
performed a constant load test at 75-80% of their peak
work rate to their limit of tolerance (Tlim, min) on the
same ergometer. Tlim was defined as the time point at
which the patients signaled to stop exercising or failed to
maintain the required pedaling rate for 10 seconds,
despite being encouragement from the investigators.
Peripheral muscle strength. Concentric isokinetic knee-
extensor strength on the dominant side was measured using
an isokinetic dynamometer (Con-TrexTM, CH 8046, Zurich,
Switzerland). After mild warm-up exercise (typically
walking around the room), the subjects were positioned
and stabilized according to a standard procedure. All
patients performed two trials of an isometric strength test
(IS) against a fixed-resistance pad at 60 ˚ (Nm). The highest
value was selected for analysis.
Statistical analysis. The Statistical Package for the Social
Sciences (SPSS, Chicago, IL, Version 13.0, 2004) statistical
software was used for the data analysis. Symmetrically
distributed baseline characteristics were summarized using
the mean¡ standard deviation (SD). Nonsymmetrical data
were expressed by the median and range. Differences
between groups were assessed with the unpaired
Student’s t-test and Mann-Whitney test, as appropriate.
The paired Student’s t-test was used to compare within-
patient variations after either hf-NMES or sham stimulation.
We anticipated a heterogeneous response to hf-NMES;11-14
therefore, to identify exercise ‘‘responders’’ to hf-NMES, we
assumed that a 10% increase in DTlim (post-pre/pre) with
no improvement after sham stimulation would indicate a
true physiological response. This cut-off was based on test-
retest data and previous experience with interventions in
COPD patients. 9,23 We then performed a logistic regression
analysis to determine the independent predictors of a
positive Tlim response to hf-NMES. A p-value less than
5% was considered statistically significant for all tests.
Sampling. We estimated the sample size in a pilot study,
in which we calculated a standardized effect size (E/S) for a
Tlim of 0.7, defined as the above-described effect size
divided by the standard deviation of DTlim (72 sec) for a
(one-sided) = 0.05 and b = 0.20. For this calculation, the
estimated sample size was 27 patients.
Role of the funding source. This study was supported
by a Research Grant from Fundaca˜o de Amparo a` Pesquisa
do Estado de Sa˜o Paulo (FAPESP - No. 01/09866-3), Brazil
(LEN).
RESULTS
Sample characteristics
As expected from the inclusion criteria, based on the
GOLD classification, patients who had a moderate to severe
airflow obstruction of 17/30 (56.6%) were considered Stage
III, and the remaining patients were classified as Stage II.17
Of note, no patient walked less than 350 m in 6 minutes (a
threshold for severe disability);24 in fact, 16/30 (53.3%)
patients walked more than 500 m. Moreover, 20/30 (66.6%)
patients had BMI values above 21 kg/m2, and only 5/30
(16.6%) of them were considered mildly FFM depleted.25
Therefore, according to the multi-dimensional BODE index
(Body-Mass Index; Airflow Obstruction; Dyspnea; Exercise
Capacity), 24/30 (80%) were in the less-severe quar-
tiles of dysfunction (BODE 0-4). 24
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hf-NMES training in COPD patients
There were no relevant side effects (e.g., skin lesions or
muscle pain) related to hf-NMES application. Based on
patient reports (diaries), the treatment was well-tolerated,
and all participants completed it. Nine COPD patients (30%)
presented with an acute exacerbation during the study,
eight of them during hf-NMES (see below). All patients
remained on hf-NMES, even during exacerbations.
There was a substantial increase in the self-adjusted
intensity of stimulation throughout the training period: the
average current amplitude increased from 30.3¡ 5.8 mA in
the first week to 48.6 ¡ 8.3 mA at the end of the treatment
(mean increase = 60.4%). Therefore, the training workload
increased markedly over the 6 weeks, as the duty cycle
increased from 16% to 33% and the total session duration
increased from 15 min/leg to 60 min/leg (i.e., the effective
stimulation time increased from approximately 2 min to
20 min/session).
Physiological responses to hf-NMES
There were no significant differences in baseline anthro-
pometric, lung function, muscle strength and exercise
capacity characteristics between patients who initially
received hf-NMES or sham stimulation (data not shown).
We also found no significant differences in the physiological
effects of hf-NMES compared to sham stimulation in the
group as a whole (Table 2). As anticipated, however, there
was large variability in the effects of hf-NMES on Tlim, with
13/28 (46.6%) subjects considered responders (mean
DTlim = 36.1%; range = 11.1 to 411.1%). These positive
changes in Tlim, however, were not followed by similar
improvements in other physiological tests, including IS,
6MWD, and peak VO2 (p.0.05; data not shown). Due to
technical problems, the VO2 peak and Tlim were evaluated
in 26 and 28 patients, respectively.
Predictors of improvement in Tlim with hf-NMES
We found that responders trained at systematically higher
stimulation intensities than nonresponders (Figure 1). The
mean stimulation intensity was significantly related to FFM
only in responders (r = 0.65; p,0.01). In addition, compared
with their counterparts, responders had higher baseline
values of FFM, 6MWD and, marginally, IS (p = 0.07)
(Table 3). Also, importantly, 6/8 (75%) patients who had
exacerbations during the hf-NMES period were nonrespon-
ders. In a logistic regression analysis that evaluated FFM,
6MWD, IS and the presence/absence of an exacerbation,
FFM was the single independent predictor of a positive Tlim
response to hf-NMES (odds ratio [95% CI] = 1.15 [1.04-1.26];
p,0.05).
DISCUSSION
This study seems to be the first sham-controlled study to
evaluate the effects of high-frequency neuromuscular elec-
trical stimulation (hf-NMES) on mildly systemically impaired
outpatients with COPD. Contrary to previously reported data
from more severe patients,9-12 hf-NMES was no more effective
than sham stimulation in the group as a whole. However,
exercise capacity (Tlim) was significantly improved in a
subgroup of ‘‘responders’’ who had a better-preserved FFM
and a higher tolerance for hf-NMES. From a practical point of
view, these data indicate that stimulus intensity (the
amplitude of the current) is a crucial training paradigm
during hf-NMES for these patients. Our results also suggest
that early training with hf-NMES before muscle wasting
begins might be useful for enhancing exercise tolerance in
COPD patients who are not yet severely disabled.
Functional effects of hf-NMES in COPD patients
Electrical stimulation has long been used in different
clinical populations to improve patients’ mobility and
tolerance of effort.13,25-26 Recently, this strategy has been
successfully tested in patients with advanced COPD,9-12 and
several systematic reviews have concluded that hf-NMES is
a promising rehabilitative option for this patient popula-
tion.27-29 However, previous investigations in COPD
patients have found some response heterogeneity.9-12 As
previously cited, part of this heterogeneity might be related
to the phenotype characteristics of the enrolled patients, as
most of them showed evidence of FFM depletion and sys-
temic disease.9-12 In fact, the present study is the first to
explore the effects of hf-NMES in mildly systemically dis-
abled patients, a population that might be intrinsically more
‘‘trainable’’ as a result of more rapid neural adaptations,
intact excitation-contraction coupling, lower thresholds for
motor unit activation and/or a higher tolerance of training
stimuli.7,15,30-31 In fact, most of the beneficial effects of hf-
NMES are likely to be related to neural adaptations, as true
hypertrophy is rarely found in patients with COPD.9-12 A
Table 2 - Changes (D) in exercise capacity and muscle strength in COPD patients after hf-NMES and sham stimulation.
Variables hf-NMES p value Sham p value Hf-NMES x Sham p value
D VO2 peak (ml/min)
# - 13.0 ¡ 136.4 0.61 -37.7 ¡ 132.3 0.15 0.792
D Tlim (s)## 129.5 ¡ 554.5 0.22 - 15.5 ¡ 278.5 0.77 0.339
D 6MWD (m) 10.2 ¡ 28.6 0.06 9.5 ¡ 37.9 0.18 0.944
D Isokinetic strength (Nm) 0.24 ¡ 11.2 0.90 1.6 ¡ 11.8 0.46 0.669
Definition of abbreviations: VO2 - oxygen uptake; Tlim - time to exercise intolerance; 6MWD – six-minute walking distance
#n = 26; ##n = 28
Figure 1 - Intensity of stimulation during hf-NMES training. Note
that ‘‘responders’’ (open squares) were training at higher levels
of intensity over six weeks than ‘‘nonresponders’’ (solid squares)
(* p,0.05).
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biopsy-based preliminary study from our group also showed
a marked dissociation between functional and structural
changes after hf-NMES in this patient population.19
There is a paucity of data regarding the physiological
effects of specific NMES training regimens.16, 30-32 However,
it is worth noting that the training protocol used in the
present study is unique in that the stimulation period and
the duty cycle (on:off ratio) were maintained for relatively
long periods. We can, therefore, speculate that although hf-
NMES has been more commonly associated with strength
and hypertrophy,16,30-32 this muscle-conditioning regimen
provided endurance-like training that impacted patients’
whole-body exercise tolerance (Tlim). In addition, an
improved endurance capacity may have further increased
patients’ mobility, thus potentiating the training effects.
Therefore, future studies with NMES should look specifi-
cally at whether this strategy is actually able to positively
impact patients’ activities of daily living.
It should be recognized that Tlim was assessed in
response to a high-intensity, constant-work-rate exercise, a
test paradigm that elicits a substantial contribution of force-
generating Type II fibers.33 Given that hf-NMES has been
associated with the selective hypertrophy of Type II fibers in
some of these patients,19 it is conceivable that the test
protocol was particularly suited to identify the physiological
benefits of these micro-structural changes. A point of
concern, however, relates to the lack of external validity of
these changes, as even the Tlim responders did not walk
further after training. Nevertheless, it should be noted that
most of the patients walked more than 500 m at baseline,
leaving little room for improvement in the 6MWD after
training.
Predictors of improvement after hf-NMES in COPD
patients
In the present study, we identified a clear physiological
response in a subgroup of responders with a better exercise
tolerance and FFM at baseline compared with nonrespon-
ders (Table 3). These data indicate that patients with less-
deteriorated muscle apparatus are likely to exhibit a more
prominent exercise response. Although nonvolitional mea-
sures of skeletal muscle function and systemic markers of
disease activity (e.g., proinflammatory and prooxidant
markers) were not measured, it can be speculated that the
training effects of hf-NMES could have been negated by the
more-impaired muscle and systemic milieu in patients with
more severe COPD.3
Additionally, it is crucial to note that the responders were
able to train at consistently higher stimulation intensities
than nonresponders (Figure 1). Although the responders
had higher FFMs (Table 3), it is likely that either they
tolerated higher training intensities and/or a given exercise
stimulus was able to provoke the recruitment of a larger
number of muscle fibers. 14,29,34 In fact, Lieber & Kelly found
that a muscle’s ability to generate tension (muscle efficiency)
is directly related to the individual’s intrinsic tissue
properties, which might include muscle mass. 15
Conversely, the nonresponders’ lower tolerance of hf-
NMES could be related to decreased subcutaneous tissue
thickness;35 however, there were no significant between-
group differences in fat mass (data not shown), and skinfold
thickness was not obtained in the present study. It seems
that the aforementioned individual characteristics may have
collectively contributed to the more impressive training
response observed in patients with better-preserved muscle
mass.
Clinical implications
A recently published systematic review of the effects of
electrical stimulation on peripheral muscle function in
COPD patients concluded that NMES has the potential to
be used as an adjunct to rehabilitation,28 especially because
passive training is associated with low metabolic and
ventilatory demands.36 The strategy was found to offer no
special advantages over volitional training in less-disabled
patients.28 However, the authors recognized that only a
single study evaluated patients with less-severe COPD,19
and the specific COPD phenotypes that might benefit from
NMES remain controversial. The present study adds novel
evidence that muscle bulk should be taken into considera-
tion when NMES is used in nondepleted patients.
Nevertheless, it should be recognized that these patients
could be more easily trained with volitional strength
programs. Therefore, from a more practical point of view,
our results offer a novel perspective for deciding whether to
use hf-NMES simultaneously or separately with voluntary
exercise in mildly impaired COPD patients.32
Study limitations
This study has some relevant limitations. The two-week
wash-out period may not have been long enough to reverse
the effects of hf-NMES in patients who received the active
intervention before the sham stimulation. However, at least
in healthy subjects, this time frame was sufficient to reverse
most of the putative neural adaptations associated with hf-
NMES.16,30 Our results reflect the influence of hf-NMES for
six weeks, and we cannot exclude the possibility that, with a
longer treatment period, the most impaired patients might
respond to this intervention. Additionally, we did not
include a control group treated with standard rehabilitation
to compare with COPD patients treated with hf-NMES.
Table 3 - Baseline characteristics of body composition,
pulmonary function, exercise capacity and peripheral
muscle strength in responders and nonresponders to hf-
NMES according to changes in exercise endurance (Tlim).
Variables
Responders
n = 13
Nonresponders
n = 15 p values
Anthropometric
BMI (kg/m2) 24.5 ¡ 4.5 23.3 ¡ 4.2 0.48
FFM (kg) 50.5 ¡ 6.4 44.5 ¡ 6.8 0.04
Lung function
FEV1 (L) 1.61 ¡ 0.4 1.35 ¡ 0.5 0.16
FEV1 (% predicted) 53.0 ¡ 13.0 48.5 ¡ 13.9 0.39
FEV1/FVC 62.7 ¡ 10.0 62.6 ¡ 11.6 0.98
RV/TLC 52.1 ¡ 9.6 54.2 ¡ 9.3 0.56
Exercise capacity
VO2 peak (%
predicted)
73.3 ¡ 17.6 70.2 ¡ 14.6 0.61
Tlim (s) 460 ¡ 79 513 ¡ 251 0.47
6MWD (m) 529 ¡ 64 468 ¡ 73 0.02
Peripheral muscle function
Isometric strength
(Nm)
146.2 ¡ 39.6 122.0 ¡ 28.4 0.07
Data are presented as the mean ¡ SD.
Definition of abbreviations: BMI – body mass index; FFM – fat-free mass;
FEV1 - forced expiratory volume in 1 second; FVC – forced vital capacity;
V˙O2 - oxygen uptake; 6MWD – six-minute walking distance
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Additionally, we did not control the subjects for such
variables as inflammatory markers or nutritional status;
however, disease exacerbations and oral steroid usage were
more common during active treatment than sham stimula-
tion. Given that the patients with exacerbations were
typically nonresponders, the potential for improvement
with hf-NMES may have been mitigated by the increased
proinflammatory burden and/or the deleterious effects of
corticosteroids on the skeletal muscles.37
CONCLUSIONS
hf-NMES improved the tolerance for high-intensity,
constant-work-rate exercise in mildly impaired COPD
patients with a better-preserved FFM and a higher tolerance
of transcutaneous stimulation. These data suggest that early
training with hf-NMES, before progressive tissue wasting
develops, may be clinically useful in enhancing exercise
tolerance in nondepleted COPD patients.
This work was supported by a Research Grant from
Fundaca˜o de Amparo a` Pesquisa do Estado de Sa˜o Paulo
(FAPESP – No. 01/09866-3), Brazil (LEN).
LMN received a Doctoral Fellowship Grant from CAPES,
and SDC received a Post-Doctoral Fellowship Grant from
FAPESP (No. 10060-3).
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